[Modern views of causes of microvascular complications development and progression in type 2 diabetes mellitus and peculiarities of their treatment].
Numerous independent studies conducted over the last decade have proved that impaired lipid metabolism is the predominant risk factor for vascular lesions of the fundus in patients with type 2 diabetes mellitus. The changes in lipid metabolism are called "the atherogenic triad of diabetes", or the metabolic syndrome, and include an increase of triglyceride level and percentage of especially atherogenic low-density lipoproteins, along with a decrease of percentage of high-density lipoproteins. Fenofibrate influences the microcirculation of patients with type 2 diabetes via normalization of mentioned parameters, thus reducing the intensity of metabolic syndrome. Moreover, fenofibrate has a non-lipid pleiotropic effect which positively influences the microvascular system even in case of a normal lipid profile. Medical treatment with fenofibrate harmoniously complements the results of retinal laser photocoagulation due to its antiapoptotic, anti-inflammatory, and antioxidant action as well as a decreasing effect on vascular reactivity.